Test Price
2,800 AEDโ Home Collection Available
ATP13A2 (PARK9) Gene Genetic Test โ 2,800 AED
Executive Summary & Core Metrics
UAE Leading Genetic Test for Early-Onset Parkinson Disease & Kufor-Rakeb Syndrome
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited Next-Generation Sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection โ Available daily from 8 AM to 11 PM.
- Clinical Guidance: Post-Test Genetic Counseling by a DHA-Licensed Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This comprehensive NGS-based test examines the entire coding region and flanking intronic boundaries of the ATP13A2 gene (PARK9), associated with autosomal recessive Kufor-Rakeb syndrome and early-onset Parkinson disease. By identifying pathogenic variants, the results empower precise clinical management, prognostication, and informed family planning in the UAE.
| Feature | Our ATP13A2 NGS Test | Closest Alternative (Single-Gene Sanger / Exome) |
|---|---|---|
| Precision & Coverage | 100% exon coverage with deep intronic variant analysis, CNV detection capability | Limited to targeted exons or may miss deep intronic mutations; variable CNV detection |
| Methodology | Next-Generation Sequencing (NGS) on Illumina platform, verified by MLPA if indicated | Sanger sequencing of selected regions or whole-exome sequencing with lower read depth |
| Turnaround Time | 3 to 4 Weeks | Typically 4โ8 Weeks |
| Clinical Utility | Gold standard for diagnostic confirmation of ATP13A2-related Parkinson and Kufor-Rakeb syndrome | May require reflex testing, delaying definitive diagnosis |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh โ Consultant Medical Genetics (DHA Registration ID: 9294403)
โThis ATP13A2 NGS test provides critical diagnostic clarity for patients presenting with early-onset parkinsonism or features suggestive of Kufor-Rakeb syndrome. Genetic results must always be integrated with a comprehensive neurological and clinical evaluation. A negative result does not exclude other genetic or neurodegenerative etiologies, and any therapeutic adjustments must be overseen by a qualified specialist.โ
Important Advisory
Do not discontinue or alter prescribed medication without consulting your physician. Changes to dopaminergic therapy based solely on genetic findings may lead to serious clinical complications.
Safety Exclusion Criteria & Urgent Care Red Flags
- Exclusion: Active systemic infection, severe immunosuppression (risk of sample degradation). Individuals unable to provide informed consent must have legal guardian authorization as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- ER Red Flags: If you experience a sudden, severe increase in Parkinsonian rigidity, recurrent falls, loss of consciousness, or new-onset seizures while awaiting results, seek emergency medical care immediately.
Patient FAQ & Clinical Guidance
1. What is the ATP13A2 (PARK9) genetic test and who should consider it?
The ATP13A2 (PARK9) Genetic Test detects disease-causing mutations in patients with early-onset parkinsonism or suspected Kufor-Rakeb syndrome for accurate diagnosis and family counseling. It is recommended for individuals with a family history of early-onset Parkinson disease, unexplained parkinsonism before age 40, or clinical features suggestive of Kufor-Rakeb syndrome including supranuclear gaze palsy, pyramidal signs, and cognitive decline.
2. How does the NGS methodology ensure accurate results and what is the turnaround time?
Our ISO-certified NGS test offers 99.9% analytical sensitivity for single nucleotide variants and copy number changes across all exons and flanking intronic regions. Results are delivered within 3 to 4 weeks from sample receipt to final comprehensive report, including variant classification and clinical interpretation.
3. Is home sample collection available and what pre-test counseling is required?
Yes, VIP mobile phlebotomy is available across all UAE emirates from 8 AM to 11 PM with temperature-controlled cold-chain transport. Pre-test genetic counseling by a DHA-licensed Consultant Medical Geneticist is mandatory to ensure informed consent and appropriate test selection. Direct insurance billing verification is available via WhatsApp at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-restricted, and processed with explicit patient consent. Clinical safety and patient consent procedures comply with Federal Decree-Law No. 4 of 2016 on Medical Liability. Genetic counseling is mandatory prior to testing.
Clinical & Logistical Metadata
| Test Name | ATP13A2 (PARK9) Gene Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina Platform |
| ICD-10-CM Code | G23.8, G20 |
| LOINC Code | 81321-3 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians